Switch to:
Also traded in: Brazil, Chile, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.65
CVS's Cash-to-Debt is ranked lower than
93% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. CVS: 0.65 )
Ranked among companies with meaningful Cash-to-Debt only.
CVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 5.05
Current: 0.65
0.04
5.05
Equity-to-Asset 0.29
CVS's Equity-to-Asset is ranked higher than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. CVS: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
CVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.51 Max: 0.67
Current: 0.29
0.29
0.67
Debt-to-Equity 1.68
CVS's Debt-to-Equity is ranked lower than
68% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. CVS: 1.68 )
Ranked among companies with meaningful Debt-to-Equity only.
CVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.34 Max: 1.68
Current: 1.68
0.04
1.68
Debt-to-EBITDA 5.41
CVS's Debt-to-EBITDA is ranked lower than
67% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. CVS: 5.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.14  Med: 1.39 Max: 5.41
Current: 5.41
1.14
5.41
Interest Coverage 7.29
CVS's Interest Coverage is ranked lower than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. CVS: 7.29 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s Interest Coverage Range Over the Past 10 Years
Min: 7.29  Med: 11.4 Max: 15.55
Current: 7.29
7.29
15.55
Piotroski F-Score: 7
Altman Z-Score: 2.86
WACC vs ROIC
6.55%
13.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.20
CVS's Operating Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. CVS: 5.20 )
Ranked among companies with meaningful Operating Margin % only.
CVS' s Operating Margin % Range Over the Past 10 Years
Min: 5.15  Med: 6.25 Max: 6.91
Current: 5.2
5.15
6.91
Net Margin % 3.59
CVS's Net Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. CVS: 3.59 )
Ranked among companies with meaningful Net Margin % only.
CVS' s Net Margin % Range Over the Past 10 Years
Min: 3  Med: 3.5 Max: 3.76
Current: 3.59
3
3.76
ROE % 18.60
CVS's ROE % is ranked higher than
65% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. CVS: 18.60 )
Ranked among companies with meaningful ROE % only.
CVS' s ROE % Range Over the Past 10 Years
Min: 9.14  Med: 11.33 Max: 18.6
Current: 18.6
9.14
18.6
ROA % 6.56
CVS's ROA % is ranked higher than
61% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. CVS: 6.56 )
Ranked among companies with meaningful ROA % only.
CVS' s ROA % Range Over the Past 10 Years
Min: 5.46  Med: 5.97 Max: 6.99
Current: 6.56
5.46
6.99
ROC (Joel Greenblatt) % 77.52
CVS's ROC (Joel Greenblatt) % is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. CVS: 77.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.74  Med: 53.38 Max: 77.52
Current: 77.52
41.74
77.52
3-Year Revenue Growth Rate 14.80
CVS's 3-Year Revenue Growth Rate is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. CVS: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 12.1 Max: 16.7
Current: 14.8
-13.3
16.7
3-Year EBITDA Growth Rate 9.70
CVS's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. CVS: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.8  Med: 8.8 Max: 21.8
Current: 9.7
-14.8
21.8
3-Year EPS without NRI Growth Rate 17.70
CVS's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. CVS: 17.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.3  Med: 15.2 Max: 112.8
Current: 17.7
-48.3
112.8
GuruFocus has detected 2 Warning Signs with CVS Health Corp CVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVS's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CVS Guru Trades in Q2 2017

First Pacific Advisors 433,092 sh (+164.76%)
Manning & Napier Advisors, Inc 296,527 sh (+109.29%)
David Dreman 26,788 sh (+93.43%)
Arnold Van Den Berg 105,540 sh (+53.73%)
Richard Pzena 700,074 sh (+31.09%)
Mairs and Power 3,254 sh (+7.25%)
Murray Stahl 2,917 sh (+5.42%)
John Buckingham 48,797 sh (+4.17%)
Jeremy Grantham 1,132,600 sh (+2.66%)
Robert Olstein 124,925 sh (+2.46%)
Tom Gayner 267,000 sh (+1.14%)
Jeff Auxier 67,449 sh (+0.60%)
Charles Brandes 94,408 sh (+0.15%)
Jerome Dodson 106,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Charles de Vaulx 1,384,235 sh (unchged)
Ray Dalio Sold Out
Richard Snow Sold Out
Jim Simons Sold Out
Ruane Cunniff Sold Out
Paul Tudor Jones Sold Out
John Rogers 115,661 sh (-0.02%)
PRIMECAP Management 3,366,250 sh (-0.74%)
Mario Gabelli 1,080,522 sh (-1.12%)
Ken Fisher 259,678 sh (-1.33%)
Barrow, Hanley, Mewhinney & Strauss 17,044,120 sh (-2.05%)
Scott Black 23,735 sh (-2.94%)
Wallace Weitz 113,291 sh (-7.23%)
Steven Cohen 192,200 sh (-8.74%)
Pioneer Investments 6,329,573 sh (-21.21%)
NWQ Managers 730,987 sh (-27.93%)
Joel Greenblatt 761,094 sh (-29.68%)
» More
Q3 2017

CVS Guru Trades in Q3 2017

Larry Robbins 1,369,003 sh (New)
Caxton Associates 3,800 sh (New)
Jeff Auxier 69,599 sh (+3.19%)
Murray Stahl 2,967 sh (+1.71%)
John Buckingham 49,528 sh (+1.50%)
Ken Fisher 261,022 sh (+0.52%)
John Rogers 115,894 sh (+0.20%)
PRIMECAP Management 3,369,520 sh (+0.10%)
Jerome Dodson 106,000 sh (unchged)
Tom Gayner 267,000 sh (unchged)
Wallace Weitz 113,291 sh (unchged)
Scott Black Sold Out
Signature Select Canadian Fund Sold Out
Richard Pzena 699,872 sh (-0.03%)
First Pacific Advisors 424,652 sh (-1.95%)
Arnold Van Den Berg 102,535 sh (-2.85%)
Mario Gabelli 1,049,236 sh (-2.90%)
Joel Greenblatt 727,254 sh (-4.45%)
Robert Olstein 119,000 sh (-4.74%)
Barrow, Hanley, Mewhinney & Strauss 16,207,787 sh (-4.91%)
David Dreman 25,417 sh (-5.12%)
Charles de Vaulx 1,310,513 sh (-5.33%)
Jeremy Grantham 1,065,011 sh (-5.97%)
Pioneer Investments 5,780,484 sh (-8.67%)
Mairs and Power 2,743 sh (-15.70%)
NWQ Managers 610,109 sh (-16.54%)
Charles Brandes 59,942 sh (-36.51%)
Manning & Napier Advisors, Inc 156,712 sh (-47.15%)
Steven Cohen 35,000 sh (-81.79%)
» More
Q4 2017

CVS Guru Trades in Q4 2017

T Rowe Price Equity Income Fund 960,000 sh (New)
Vanguard Health Care Fund 3,308,218 sh (New)
Ray Dalio 420,695 sh (New)
Jim Simons 1,888,705 sh (New)
Paul Tudor Jones 28,220 sh (New)
Bill Nygren 2,700,000 sh (New)
Steven Cohen 1,390,989 sh (+3874.25%)
Larry Robbins 6,821,631 sh (+398.29%)
Caxton Associates 14,743 sh (+287.97%)
Joel Greenblatt 951,796 sh (+30.88%)
Robert Olstein 136,500 sh (+14.71%)
Charles Brandes 60,383 sh (+0.74%)
PRIMECAP Management 3,393,733 sh (+0.72%)
Richard Pzena 701,082 sh (+0.17%)
Tom Gayner 267,000 sh (unchged)
Jerome Dodson Sold Out
Arnold Van Den Berg Sold Out
John Rogers Sold Out
Mairs and Power Sold Out
Murray Stahl Sold Out
Wallace Weitz Sold Out
Jeff Auxier 69,359 sh (-0.34%)
Jeremy Grantham 1,058,311 sh (-0.63%)
Barrow, Hanley, Mewhinney & Strauss 15,514,373 sh (-4.28%)
John Buckingham 45,335 sh (-8.47%)
Ken Fisher 233,346 sh (-10.60%)
Mario Gabelli 765,246 sh (-27.07%)
Charles de Vaulx 699,939 sh (-46.59%)
David Dreman 10,434 sh (-58.95%)
Pioneer Investments 1,359,849 sh (-76.48%)
First Pacific Advisors 61,560 sh (-85.50%)
NWQ Managers 73,212 sh (-88.00%)
» More
Q1 2018

CVS Guru Trades in Q1 2018

Jerome Dodson 346,000 sh (New)
Andreas Halvorsen 950,311 sh (New)
T Rowe Price Equity Income Fund 2,390,000 sh (+148.96%)
Bill Nygren 6,300,000 sh (+133.33%)
Ray Dalio 670,184 sh (+59.30%)
Vanguard Health Care Fund 4,518,118 sh (+36.57%)
Robert Olstein 185,000 sh (+35.53%)
Paul Tudor Jones 36,809 sh (+30.44%)
Ken Fisher 300,425 sh (+28.75%)
Caxton Associates 17,245 sh (+16.97%)
Barrow, Hanley, Mewhinney & Strauss 18,102,755 sh (+16.68%)
Larry Robbins 7,794,388 sh (+14.26%)
Pioneer Investments 1,477,571 sh (+8.66%)
Tom Gayner 275,000 sh (+3.00%)
Jim Simons 1,919,505 sh (+1.63%)
Richard Pzena 703,641 sh (+0.37%)
Jeff Auxier 69,614 sh (+0.37%)
Jeremy Grantham 220,000 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Charles Brandes 60,137 sh (-0.41%)
PRIMECAP Management 3,377,691 sh (-0.47%)
John Buckingham 43,252 sh (-4.59%)
David Dreman 9,331 sh (-10.57%)
Mario Gabelli 657,470 sh (-14.08%)
First Pacific Advisors 52,660 sh (-14.46%)
Charles de Vaulx 480,122 sh (-31.41%)
Steven Cohen 814,500 sh (-41.44%)
Joel Greenblatt 512,294 sh (-46.18%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Add 16.68%0.26%$60.6 - $83.63 $ 67.74-6%18,102,755
Bill Nygren 2018-03-31 Add 133.33%1.21%$60.6 - $83.63 $ 67.74-6%6,300,000
Vanguard Health Care Fund 2018-03-31 Add 36.57%0.17%$60.6 - $83.63 $ 67.74-6%4,518,118
T Rowe Price Equity Income Fund 2018-03-31 Add 148.96%0.44%$60.6 - $83.63 $ 67.74-6%2,390,000
Richard Pzena 2018-03-31 Add 0.37%$60.6 - $83.63 $ 67.74-6%703,641
Mario Gabelli 2018-03-31 Reduce -14.08%0.05%$60.6 - $83.63 $ 67.74-6%657,470
Joel Greenblatt 2018-03-31 Reduce -46.18%0.46%$60.6 - $83.63 $ 67.74-6%512,294
Ken Fisher 2018-03-31 Add 28.75%$60.6 - $83.63 $ 67.74-6%300,425
Tom Gayner 2018-03-31 Add 3.00%0.01%$60.6 - $83.63 $ 67.74-6%275,000
Robert Olstein 2018-03-31 Add 35.53%0.38%$60.6 - $83.63 $ 67.74-6%185,000
Charles Brandes 2018-03-31 Reduce -0.41%$60.6 - $83.63 $ 67.74-6%60,137
David Dreman 2018-03-31 Reduce -10.57%0.05%$60.6 - $83.63 $ 67.74-6%9,331
NWQ Managers 2018-03-31 Sold Out 0.08%$60.6 - $83.63 $ 67.74-6%0
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -4.28%0.09%$66.8 - $80.91 $ 67.74-7%15,514,373
Vanguard Health Care Fund 2017-12-31 New Buy0.52%$66.8 - $80.91 $ 67.74-7%3,308,218
Bill Nygren 2017-12-31 New Buy1.05%$66.8 - $80.91 $ 67.74-7%2,700,000
T Rowe Price Equity Income Fund 2017-12-31 New Buy0.32%$66.8 - $80.91 $ 67.74-7%960,000
Joel Greenblatt 2017-12-31 Add 30.88%0.24%$66.8 - $80.91 $ 67.74-7%951,796
Mario Gabelli 2017-12-31 Reduce -27.07%0.14%$66.8 - $80.91 $ 67.74-7%765,246
Richard Pzena 2017-12-31 Add 0.17%$66.8 - $80.91 $ 67.74-7%701,082
Ken Fisher 2017-12-31 Reduce -10.60%$66.8 - $80.91 $ 67.74-7%233,346
Robert Olstein 2017-12-31 Add 14.71%0.16%$66.8 - $80.91 $ 67.74-7%136,500
NWQ Managers 2017-12-31 Reduce -88.00%0.63%$66.8 - $80.91 $ 67.74-7%73,212
Charles Brandes 2017-12-31 Add 0.74%$66.8 - $80.91 $ 67.74-7%60,383
David Dreman 2017-12-31 Reduce -58.95%0.67%$66.8 - $80.91 $ 67.74-7%10,434
Wallace Weitz 2017-12-31 Sold Out 0.39%$66.8 - $80.91 $ 67.74-7%0
John Rogers 2017-12-31 Sold Out 0.11%$66.8 - $80.91 $ 67.74-7%0
Arnold Van Den Berg 2017-12-31 Sold Out 1.17%$66.8 - $80.91 $ 67.74-7%0
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -4.91%0.1%$75.35 - $83.31 $ 67.74-14%16,207,787
Mario Gabelli 2017-09-30 Reduce -2.90%0.02%$75.35 - $83.31 $ 67.74-14%1,049,236
Joel Greenblatt 2017-09-30 Reduce -4.45%0.04%$75.35 - $83.31 $ 67.74-14%727,254
Richard Pzena 2017-09-30 Reduce -0.03%$75.35 - $83.31 $ 67.74-14%699,872
NWQ Managers 2017-09-30 Reduce -16.54%0.13%$75.35 - $83.31 $ 67.74-14%610,109
Ken Fisher 2017-09-30 Add 0.52%$75.35 - $83.31 $ 67.74-14%261,022
Robert Olstein 2017-09-30 Reduce -4.74%0.06%$75.35 - $83.31 $ 67.74-14%119,000
John Rogers 2017-09-30 Add 0.20%$75.35 - $83.31 $ 67.74-14%115,894
Arnold Van Den Berg 2017-09-30 Reduce -2.85%0.04%$75.35 - $83.31 $ 67.74-14%102,535
Charles Brandes 2017-09-30 Reduce -36.51%0.04%$75.35 - $83.31 $ 67.74-14%59,942
David Dreman 2017-09-30 Reduce -5.12%0.06%$75.35 - $83.31 $ 67.74-14%25,417
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -2.05%0.04%$75.95 - $82.79 $ 67.74-14%17,044,120
Mario Gabelli 2017-06-30 Reduce -1.12%0.01%$75.95 - $82.79 $ 67.74-14%1,080,522
Joel Greenblatt 2017-06-30 Reduce -29.68%0.32%$75.95 - $82.79 $ 67.74-14%761,094
NWQ Managers 2017-06-30 Reduce -27.93%0.3%$75.95 - $82.79 $ 67.74-14%730,987
Richard Pzena 2017-06-30 Add 31.09%0.07%$75.95 - $82.79 $ 67.74-14%700,074
Tom Gayner 2017-06-30 Add 1.14%0.01%$75.95 - $82.79 $ 67.74-14%267,000
Ken Fisher 2017-06-30 Reduce -1.33%$75.95 - $82.79 $ 67.74-14%259,678
Robert Olstein 2017-06-30 Add 2.46%0.03%$75.95 - $82.79 $ 67.74-14%124,925
John Rogers 2017-06-30 Reduce -0.02%$75.95 - $82.79 $ 67.74-14%115,661
Wallace Weitz 2017-06-30 Reduce -7.23%0.03%$75.95 - $82.79 $ 67.74-14%113,291
Arnold Van Den Berg 2017-06-30 Add 53.73%0.46%$75.95 - $82.79 $ 67.74-14%105,540
Charles Brandes 2017-06-30 Add 0.15%$75.95 - $82.79 $ 67.74-14%94,408
David Dreman 2017-06-30 Add 93.43%0.57%$75.95 - $82.79 $ 67.74-14%26,788
Ruane Cunniff 2017-06-30 Sold Out 0.01%$75.95 - $82.79 $ 67.74-14%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 621399    SIC: 8099
Compare:NYSE:ANTM, NYSE:AET, NAS:ESRX, NYSE:CI, NYSE:HUM, NYSE:CNC, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:CVSH34.Brazil, CVS.Chile, CVS.Germany, CVS.Mexico,
Headquarter Location:USA
CVS Health Corp operates in the healthcare sector. Its primary business is that of operating retail pharmacies. The company has three reportable segments namely Pharmacy Services, Retail/LTC, and Corporate.

CVS Health has vertically integrated one of the largest retail pharmacy chains in the United States with one of the largest pharmacy benefit managers. This combination makes it one of the premier healthcare firms in the U.S. The company processes approximately 1.3 billion prescriptions per year and operates more than 10,000 retail pharmacies across the U.S. The firm is now seeking to acquire Aetna, which will further extend its vertical reach and create the most integrated healthcare player in the U.S.

Guru Investment Theses on CVS Health Corp

Bill Nygren Comments on CVS Health Corp - Jan 11, 2018

CVS Health Corporation (CVS - $73)(NYSE:CVS)
CVS is well positioned in a U.S. health care system that rewards scale, as the company owns the nation’s largest pharmacy benefit manager (PBM), the largest retail pharmacy and the largest retail clinic. Both the PBM and retail pharmacy segments are as concentrated as they have ever been, and we believe these lines of business protect existing players and pose serious challenges for new entrants. After underperforming the S&P 500 by nearly 60% over the past two years, CVS is now valued at less than 12x next year’s consensus earnings after adding back amortization of intangible assets. In our view, the market is underestimating the durability of the company’s competitive advantages across multiple end markets. Additionally, the pending acquisition of Aetna, Inc. would bring together two forward-thinking management teams and give them a broad suite of assets through which to address sector-wide trends, like the shift toward value-based care models and the increasing “consumerization” of health care.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2017 commentary.

Check out Bill Nygren latest stock trades

Weitz Funds Comments on CVS Health - Jan 26, 2017

CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on CVS Health Corp - Nov 02, 2016

CVS Health Corp. (NYSE:CVS) (2.3%) (CVS – $88.99 – NYSE) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The stock declined in the quarter due to the significant political scrutiny around drug pricing. Efforts to regulate and control drug pricing could have an indirect impact on CVS’s revenues and earnings. However, we believe the company is a low cost provider who already works aggressively to improve health through the dispensing of low cost generic drugs, coordination of care, and efforts to improve adherence by patients.



From Mario Gabelli (Trades, Portfolio)'s Equity Income Fund 3rd quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about CVS Health Corp

Merger Mania: Companies Are Emboldened by Court Ruling A dive into the fundamentals of CVS and Aetna. As the companies prepare to face antitrust regulators, the markets like what they see
It’s called merger mania. Also waiting to tie the knot: Retail pharmacy giant CVS Health (NYSE:CVS) and its betrothed, heath insurer Aetna (NYSE:AET). Read more...
CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Virginia to Help Combat Opioid Abuse
CVS Health Applauds New Law Expanding Veterans' Access to High-Quality, Cost-Effective Walk-In Care Providers
CVS Health Announces Management Team for Combined Company Following Close of Aetna Acquisition Transaction
Barrow, Hanley, Mewhinney & Strauss Boosts Several Positions in 1st Quarter Firm adds to Comcast, Exelon, Adient
Investment firm Barrow, Hanley, Mewhinney & Strauss invested in the following stocks in the first quarter.  Read more...
Thinking about buying stock in Apple, CVS Health Corp, Facebook, Symantec and Trade Desk?
Weekly Top Insider Buys Highlight for the Week of May 11 The largest Insider Buys this week were for American Express Co. (AXP), MetLife Inc. (MET), American International Group Inc. (AIG), and CVS Health Corp. (CVS).
The largest Insider Buys this week were for American Express Co. (NYSE:AXP), MetLife Inc. (NYSE:MET), American International Group Inc. (NYSE:AIG), and CVS Health Corp. (NYSE:CVS). Read more...
CVS Health Statement on Trump Administration Initiative to Reduce Drug Costs
At HLTH 2018, CVS Health Chief Medical Officer Shows How Complementary Care Management at Retail Can Enhance Population Health
Stocks That Fell to 3-Year Lows in the Week of May 4 AT&T Inc., Gilead Sciences Inc., CVS Health Corp., and Cardinal Health Inc. have declined to their respective three-year lows
AT&T Inc. (NYSE:T), Gilead Sciences Inc. (NASDAQ:GILD), CVS Health Corp. (NYSE:CVS) and Cardinal Health Inc. (NYSE:CAH) have declined to their three-year lows. Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.41
CVS's PE Ratio is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 10.41 )
Ranked among companies with meaningful PE Ratio only.
CVS' s PE Ratio Range Over the Past 10 Years
Min: 9.35  Med: 16.67 Max: 27.17
Current: 10.41
9.35
27.17
Forward PE Ratio 10.01
CVS's Forward PE Ratio is ranked higher than
85% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. CVS: 10.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.41
CVS's PE Ratio without NRI is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 10.41 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.35  Med: 16.58 Max: 27.17
Current: 10.41
9.35
27.17
Price-to-Owner-Earnings 16.19
CVS's Price-to-Owner-Earnings is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. CVS: 16.19 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.51  Med: 17.21 Max: 51.08
Current: 16.19
8.51
51.08
PB Ratio 1.78
CVS's PB Ratio is ranked higher than
88% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. CVS: 1.78 )
Ranked among companies with meaningful PB Ratio only.
CVS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.81 Max: 3.37
Current: 1.78
1.01
3.37
PS Ratio 0.37
CVS's PS Ratio is ranked higher than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. CVS: 0.37 )
Ranked among companies with meaningful PS Ratio only.
CVS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.54 Max: 0.88
Current: 0.37
0.33
0.88
Price-to-Free-Cash-Flow 14.16
CVS's Price-to-Free-Cash-Flow is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. CVS: 14.16 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.28  Med: 18.92 Max: 78.67
Current: 14.16
8.28
78.67
Price-to-Operating-Cash-Flow 10.13
CVS's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. CVS: 10.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.72  Med: 11.43 Max: 19.92
Current: 10.13
6.72
19.92
EV-to-EBIT 9.63
CVS's EV-to-EBIT is ranked higher than
86% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. CVS: 9.63 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.8 Max: 20.2
Current: 9.63
6.3
20.2
EV-to-EBITDA 7.63
CVS's EV-to-EBITDA is ranked higher than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. CVS: 7.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.7 Max: 15.9
Current: 7.63
5.1
15.9
EV-to-Revenue 0.49
CVS's EV-to-Revenue is ranked higher than
74% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. CVS: 0.49 )
Ranked among companies with meaningful EV-to-Revenue only.
CVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.6 Max: 1.2
Current: 0.49
0.4
1.2
PEG Ratio 0.90
CVS's PEG Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 0.90 )
Ranked among companies with meaningful PEG Ratio only.
CVS' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.31 Max: 2.35
Current: 0.9
0.57
2.35
Shiller PE Ratio 17.02
CVS's Shiller PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. CVS: 17.02 )
Ranked among companies with meaningful Shiller PE Ratio only.
CVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.29  Med: 23.59 Max: 38.78
Current: 17.02
15.29
38.78
Current Ratio 2.37
CVS's Current Ratio is ranked lower than
64% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 2.37 )
Ranked among companies with meaningful Current Ratio only.
CVS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.53 Max: 2.64
Current: 2.37
1.02
2.64
Quick Ratio 1.88
CVS's Quick Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.51 Max: 1.88
Current: 1.88
0.2
1.88
Days Inventory 33.84
CVS's Days Inventory is ranked lower than
82% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. CVS: 33.84 )
Ranked among companies with meaningful Days Inventory only.
CVS' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 38.68 Max: 50.81
Current: 33.84
35.11
50.81
Days Sales Outstanding 27.41
CVS's Days Sales Outstanding is ranked higher than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. CVS: 27.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.77  Med: 23.74 Max: 28.31
Current: 27.41
18.77
28.31
Days Payable 17.98
CVS's Days Payable is ranked lower than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. CVS: 17.98 )
Ranked among companies with meaningful Days Payable only.
CVS' s Days Payable Range Over the Past 10 Years
Min: 16.69  Med: 19.59 Max: 21.57
Current: 17.98
16.69
21.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.96
CVS's Dividend Yield % is ranked higher than
84% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 2.96 )
Ranked among companies with meaningful Dividend Yield % only.
CVS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.49  Med: 1.23 Max: 3.29
Current: 2.96
0.49
3.29
Dividend Payout Ratio 0.31
CVS's Dividend Payout Ratio is ranked lower than
53% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.27 vs. CVS: 0.31 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.23 Max: 0.35
Current: 0.31
0.11
0.35
3-Year Dividend Growth Rate 22.10
CVS's 3-Year Dividend Growth Rate is ranked higher than
62% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.40 vs. CVS: 22.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8 Max: 37
Current: 22.1
-33.8
37
Forward Dividend Yield % 2.85
CVS's Forward Dividend Yield % is ranked higher than
82% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.33 vs. CVS: 2.85 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 9.00
CVS's 5-Year Yield-on-Cost % is ranked higher than
84% of the 38 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.89 vs. CVS: 9.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.49  Med: 3.71 Max: 10
Current: 9
1.49
10
3-Year Average Share Buyback Ratio 3.80
CVS's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. CVS: 3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -0.4 Max: 4.7
Current: 3.8
-22.9
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.60
CVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. CVS: 0.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.36 Max: 26.44
Current: 0.6
0.55
26.44
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.63
CVS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 0.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CVS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 0.74 Max: 1.48
Current: 0.63
0.54
1.48
Price-to-Median-PS-Value 0.69
CVS's Price-to-Median-PS-Value is ranked higher than
83% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. CVS: 0.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 0.99 Max: 2.75
Current: 0.69
0.47
2.75
Price-to-Peter-Lynch-Fair-Value 0.99
CVS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. CVS: 0.99 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CVS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.59 Max: 36.41
Current: 0.99
0.64
36.41
Earnings Yield (Greenblatt) % 10.38
CVS's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. CVS: 10.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5  Med: 9.2 Max: 16
Current: 10.38
5
16
Forward Rate of Return (Yacktman) % 18.65
CVS's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. CVS: 18.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.7  Med: 18.1 Max: 20.6
Current: 18.65
11.7
20.6

More Statistics

Revenue (TTM) (Mil) $185,944.00
EPS (TTM) $ 6.51
Beta0.85
Volatility33.78%
52-Week Range $60.14 - 84.00
Shares Outstanding (Mil)1,016.65

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 209,686 262,300 280,846
EBIT (Mil $) 13,251 15,791 18,365
EBITDA (Mil $) 14,018 16,848 17,014
EPS ($) 6.11 7.95 9.07
EPS without NRI ($) 6.11 7.95 9.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.71%
Dividends per Share ($) 1.93 2.03 2.25

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}